CNSX:VREOPharmaceuticals
Vireo Growth (CNSX:VREO) Trailing US$63.4m Loss Tests Bullish Valuation Narratives
Vireo Growth (CNSX:VREO) has released its FY 2025 numbers, reporting third quarter revenue of US$91.7 million and a basic EPS loss of US$0.03, alongside a trailing twelve month loss of US$63.4 million on revenue of US$189.3 million. Over recent quarters the company’s revenue moved from US$25.2 million in Q2 2024 to US$25.0 million in Q4 2024, then to US$24.5 million, US$48.1 million and US$91.7 million across Q1 to Q3 2025. Quarterly basic EPS remained in loss-making territory between roughly...